Phase II study of NS-17 in elderly patients with acute myeloid leukemia
Latest Information Update: 10 Jan 2022
Price :
$35 *
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Cytarabine; Cytarabine; Daunorubicin; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Nippon Shinyaku
- 22 Dec 2021 Status changed from recruiting to completed.
- 09 Dec 2021 New trial record